Shanghai Pharmaceuticals Gains Approval for New Cholesterol Drug Production

Stock News07-30

Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a Drug Registration Certificate (Certificate No.: 2026S02581) from the National Medical Products Administration for the production of Rosuvastatin and Ezetimibe Tablets (I).

The drug, which is indicated for hypercholesterolemia or homozygous familial hypercholesterolemia (HoFH), was originally developed by Sanofi-aventis, S.R.O. and launched in the European Union in July 2014 under the brand name Zenon Neo.

In December 2024, Changzhou Pharmaceutical Factory submitted a registration application for the drug to the National Medical Products Administration, which was subsequently accepted. As of the announcement date, the company has invested approximately RMB 9.68 million in research and development for this drug.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132479461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132479461","market":"other","top_or_hot":-1,"title":"Shanghai Pharmaceuticals Gains Approval for New Cholesterol Drug Production","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a Drug Registration Certificate (Certificate No.: 2026S02581) from the National Medical Products Administration for the production of Rosuvastatin and Ezetimibe Tablets (I).<br><br>The drug, which is indicated for hypercholesterolemia or homozygous familial hypercholesterolemia (HoFH), was originally developed by Sanofi-aventis, S.R.O. and launched in the European Union in July 2014 under the brand name Zenon Neo.<br><br>In December 2024, Changzhou Pharmaceutical Factory submitted a registration application for the drug to the National Medical Products Administration, which was subsequently accepted. As of the announcement date, the company has invested approximately RMB 9.68 million in research and development for this drug.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals Gains Approval for New Cholesterol Drug Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals Gains Approval for New Cholesterol Drug Production\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-30 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a Drug Registration Certificate (Certificate No.: 2026S02581) from the National Medical Products Administration for the production of Rosuvastatin and Ezetimibe Tablets (I).<br><br>The drug, which is indicated for hypercholesterolemia or homozygous familial hypercholesterolemia (HoFH), was originally developed by Sanofi-aventis, S.R.O. and launched in the European Union in July 2014 under the brand name Zenon Neo.<br><br>In December 2024, Changzhou Pharmaceutical Factory submitted a registration application for the drug to the National Medical Products Administration, which was subsequently accepted. As of the announcement date, the company has invested approximately RMB 9.68 million in research and development for this drug.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1132479461","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132479461","pubTimestamp":1785398792,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a Drug Registration Certificate (Certificate No.:...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0196":"行业龙头","BK0184":"上海国资改革","BK0012":"证金概念","BK0187":"一线龙头","02607":"上海医药","BK0097":"医药电商","BK0099":"上海本地重组","BK0028":"国家队","BK1197":"保健护理产品经销商","BK0020":"浦东新区","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","BK0175":"白马股"},"translate_title":"上海医药获得胆固醇新药生产批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) has announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received a Drug Registration Certificate (Certificate No.: 2026S02581) from the National Medical Products Administration for the production of Rosuvastatin and Ezetimibe Tablets (I).The drug, which is indicated for hypercholesterolemia or homozygous familial hypercholesterolemia (HoFH), was originally developed by Sanofi-aventis, S.R.O. and launched in the European Union in July 2014 under the brand name Zenon Neo.In December 2024, Changzhou Pharmaceutical Factory submitted a registration application for the drug to the National Medical Products Administration, which was subsequently accepted. As of the announcement date, the company has invested approximately RMB 9.68 million in research and development for this drug.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132479461","isCrawlerRequest":true}